Trial Profile
A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CanStem303C
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology
- 03 Jul 2021 Overall survival results presented at the 23rd World Congress on Gastrointestinal Cancer
- 22 Jun 2021 Status changed from active, no longer recruiting to completed.
- 23 May 2021 This trial has been completed in Belgium and Netherlands, according to European Clinical Trials Database record.